Anaptysbio (ANAB) Net Income towards Common Stockholders Growth (3y) (2019 - 2026)
Anaptysbio (ANAB) Net Income towards Common Stockholders Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 144.84% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Anaptysbio | 1.55 Bn | 1.27 Bn | - | 5.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.44% |
| Dec 31, 2025 | 61.48% |
| Sep 30, 2025 | 33.92% |
| Jun 30, 2025 | 8.89% |
| Mar 31, 2025 | 11.31% |
| Dec 31, 2024 | 31.45% |
| Sep 30, 2024 | 0.83% |
| Jun 30, 2024 | -21.21% |
| Mar 31, 2024 | -7.50% |
| Dec 31, 2023 | -48.17% |
| Sep 30, 2023 | -16.22% |
| Jun 30, 2023 | -22.74% |
| Mar 31, 2023 | -96.36% |
| Dec 31, 2022 | -3.89% |
| Sep 30, 2022 | -6.63% |
| Jun 30, 2022 | -28.70% |
| Mar 31, 2022 | -36.68% |
| Dec 31, 2021 | -23.65% |
| Sep 30, 2021 | -28.28% |
| Jun 30, 2021 | -24.38% |